Case Study

Pharmagroup Int. and Fluvera: When subsidiary governance means losing competitive ground

9 pages
October 2006
Reference: IMD-3-1706

Pharmagroup Int. faces difficulties in finishing the development and getting to the market an new, strategically important product. The product was created by a US start up, that had originally formed a strategic Joint Venture with Pharmagroup, but was then more and more integrated into the group because of difficulties in R&D that Pharmagroup was unable to control and overcome. Now, R&D takes place in a fully owned US subsidiary but Pharmagroup is still unable to make considerable progress with the current governance system. The learning objective is to understand the importance of subsidiary governance and its business dimension in multinational groups, to identify key problems and causes in the setting and to design a subsidiary governance system for the US operations that leads to efficient and timely conclusion of development and market launch.

Corporate Governance, Subsidiary Company, Pharmaceuticals
Europe, United States of America
Healthcare, Pharmaceuticals
Generalized Experience
© 2006
Available Languages
Case clearing houses
IMD case studies are distributed through case clearing houses. In order to browse the collection and purchase copies please visit the links below.

The Case Centre

Cranfield University

Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]

Harvard Business School Publishing

60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]

Asia Pacific Case Center

NUCB Business School

1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]


Research Information & Knowledge Hub for additional information on IMD publications

Discover our latest research
IMD's faculty and research teams publish articles, case studies, books and reports on a wide range of topics